Technology
Health
Medical

Neurotrope

$5.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.35 (7.45%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Neurotrope and other stocks, options, ETFs, and crypto commission-free!

About

Neurotrope, Inc. Common Stock, also called Neurotrope, is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. Read More The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.

Employees
6
Headquarters
New York, New York
Founded
2011
Market Cap
60.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
33.47K
High Today
$5.60
Low Today
$4.93
Open Price
$5.15
Volume
350.66K
52 Week High
$11.93
52 Week Low
$3.33

Collections

Technology
Health
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO
US
North America

News

PR NewswireMar 11

Neurotrope Reports Year End 2018 Financial Results

NEW YORK, March 11, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease ("AD"), provided financial results for the year ended December 31, 2018. As of December 31, 2018, the Company had approximately $28.8 million of cash and cash equivalents. The Company raised approximately $20.5 million of net cash proceeds in December 2018. With these funds and its cash on hand, the Compa...

15
MarketBeatMar 8

Stock Price, News, & Analysis for Neurotrope

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company has a license agreement with The Board of Trustees of the Leland Sta...

13
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.